| (Values in U.S. Thousands) | Jun, 2016 | Mar, 2016 | Dec, 2015 | Sep, 2015 | Jun, 2015 |
| Sales | -9,999,000 | 800 | 410 | 220 | 50 |
| Sales Growth | -1,249,973.44% | +95.12% | +86.36% | +339.99% | +66.67% |
| Net Income | -9,999,000 | -16,270 | -15,390 | -13,990 | -15,290 |
| Net Income Growth | -61,356.67% | -5.72% | -10.01% | +8.50% | -103.32% |
Epirus Biopharm Inc (EPRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
EPIRUS Biopharmaceuticals Inc. is a biopharmaceutical company. It is focused on the development and commercialization of biosimilar monoclonal antibodies. Its products include BOW015, a monoclonal antibody against tumor necrosis factor alpha, used to treat autoimmune diseases. EPIRUS Biopharmaceuticals Inc., formerly known as Zalicus Inc., is based in Boston, Massachusetts.